



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR 2 8 2005

Ms. Vivian Kelly Regulatory Affairs Consultant Howmedica Osteonics Corporation 59 Route 17 Allendale, NJ 07401-1677

Re: K032244

Trade/Device Name: Gamma 3 Nail System Regulation Number: 21 CFR 888.3020 Regulation Name: Intramedullary fixation rod

Regulatory Class: II Product Code: HSB Dated: July 16,2003 Received: July 22,2003

Dear Ms. Kelly:

This letter corrects our substantially equivalent letter of August 8, 2003 regarding the Regulation Number, Regulation Name and Product Code of the above device. The correct information is listed above.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not

limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Miriam Provost, Ph.D.

Acting Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

510(k) Nurnber (if known): K O 32244

Device Name: Gamma 3 Nail System

**Indications** For Use:

The intended use of the subject Trochanteric Gamma 3 Nail is identical to that of the predicate Trochanteric Dyax <sup>®</sup> and **Gamma** <sup>®</sup> Nails. The product is intended for use in stabilizing various types of intertrochanteric fractures of the femur.

Muram C Provost
(Division Sign-Off)
Division of General, Restorative

and Neurological Devices

510(k) Number — べる32244—

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ——

OR

Over-The-Counter Use —

(Per 21 CFR 801.109)

(Optional Format 1-2-96)

## AUG - 8 2003

# K032244 Page 10F1 **Summary of Safety and Effectiveness**

# Line Extension to the Trochanteric Dyax® & Gamma® Nail Systems

#### **Submission Information**

Name and Address of the Sponsor

of the 510(k) Submission:

Howmedica Osteonics Corp

59 Route 17

Allendale, NJ 07401-1677

Contact Person:

Vivian Kelly

Regulatory Affairs Consultant

Phone: 201-831-5581 Fax: 201-831-6038

Date of Summary Preparation:

July 16, 2003

### **Device Identification**

Proprietary Name:

Gamma 3 Nail System

Common Name:

Intramedullary Nail

Classification Name and Reference: Intramedullary Fixation Rod, 21 CFR §888.3020

This Special 510(k) submission is a line extension to the Trochanteric Dyax<sup>®</sup> and Gamma<sup>®</sup> Nail Systems. This line extension is intended to address a material modification and design modifications to the predicate Trochanteric Dyax<sup>®</sup> and Gamma<sup>®</sup> Nail Systems. Both the subject and predicate systems offer trochanteric nails, and offer various accessories such as lag screws, locking screws, set screws. and end caps.

The intended use of the subject device is identical to that of the predicate Trochanteric Dyax ® Nails. The device is intended for use in stabilizing various types of intertrochanteric fractures of the femur. The Trochanteric Gamma 3 Nail in the Gamma 3 Nail System also has the same basic design concepts as the currently available Trochanteric Dyax® and Gamma® Nail Systems. Mechanical testing demonstrated comparable mechanical properties to the predicate components.